Celcuity, Inc. $CELC Shares Acquired by Wellington Management Group LLP

Key Points

• Wellington Management more than doubled its Celcuity stake in the second quarter, purchasing 477,643 additional shares to own 906,595 shares valued at approximately $94.8 million, or 1.86% of the company.
• Celcuity shares opened at $91.98, while the company reported a quarterly loss of $1.44 per share, missing analysts’ consensus estimate of a $1.16 loss. Institutional investors and hedge funds collectively own 63.33% of the stock.
• Analyst sentiment remains positive, with 10 Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $154.55, well above the current share price.

Wellington Management Group LLP increased its position in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) by 111.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 906,595 shares of the company's stock after purchasing an additional 477,643 shares during the quarter. Wellington Management Group LLP owned 1.86% of Celcuity worth $94,848,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of CELC. Parallel Advisors LLC acquired a new position in Celcuity in the 1st quarter worth approximately $38,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock valued at $34,000 after acquiring an additional 319 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Celcuity in the 4th quarter valued at $42,000. PNC Financial Services Group Inc. increased its stake in shares of Celcuity by 20.1% in the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company's stock worth $59,000 after acquiring an additional 86 shares during the period. Finally, KBC Group NV acquired a new stake in shares of Celcuity in the first quarter worth $64,000. Institutional investors and hedge funds own 63.33% of the company's stock.

Celcuity Stock Up 3.3%

CELC opened at $91.98 on Wednesday. The company has a fifty day moving average of $94.66 and a two-hundred day moving average of $106.96. The stock has a market capitalization of $4.50 billion, a price-to-earnings ratio of -21.39 and a beta of 0.21. Celcuity, Inc. has a fifty-two week low of $44.42 and a fifty-two week high of $151.02. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.28). On average, research analysts expect that Celcuity, Inc. will post -4.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on CELC. Macquarie Infrastructure set a $160.00 price target on shares of Celcuity in a report on Thursday, May 28th. Citizens Jmp reissued a "market outperform" rating and issued a $177.00 price objective on shares of Celcuity in a report on Monday, August 17th. Wells Fargo & Company lowered their target price on Celcuity from $183.00 to $166.00 and set an "overweight" rating on the stock in a research note on Wednesday, June 3rd. Guggenheim raised their target price on Celcuity from $165.00 to $175.00 and gave the stock a "buy" rating in a report on Monday, August 17th. Finally, HC Wainwright reiterated a "buy" rating and set a $155.00 price target on shares of Celcuity in a research report on Friday, August 14th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $154.55.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source